Stock listing

gettex:BX20 BioXcel Therapeutics, Inc. Aktie

German listing (gettex) of BioXcel Therapeutics, Inc. · home listing NASDAQ:BTAI

Follow BioXcel Therapeutics, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:BTAI

$0.013 USD -0.000 (-3.6%)

Close on Oct 30, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:BTAI · Data provided by Twelve Data

Past year -99.4% · daily closes, Oct 30, 2025 – Oct 30, 2026, adjusted for splits
Day range
$0.012 – $0.016 USDOct 30, 2026
Volume
114,934 sharesOct 30, 2026
Market cap
$406,965 USDAt the close on Oct 30, 2026 · price × 31.30M shares outstanding
52-week range
$0.012 – $2.329 USDLowest and highest trades, Oct 31, 2025 – Oct 30, 2026
Traded on an average day
$1.10M USDMedian day 695,500 shares · last 3 months, Jul 30, 2026 – Oct 30, 2026
BioXcel Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:BTAI · Home$0.013 USD0.000 (-3.6%)114,934$0.012$0.016$0.012$0.013Close on Oct 30, 2026

Data provided by Twelve Data

Daily closes

Last 3 months, Jul 30, 2026 – Oct 30, 2026 · NASDAQ:BTAI · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.0130.000-3.6%$0.012$0.016$0.012114,934
$0.013-0.002-13.0%$0.016$0.017$0.012119,152
$0.016+0.002+14.6%$0.012$0.016$0.012132,057
$0.014-0.002-14.9%$0.016$0.016$0.01245,828
$0.016-0.032-66.8%$0.013$0.016$0.012151,009
$0.048-0.002-3.3%$0.045$0.055$0.04070,578
$0.050-0.003-6.2%$0.056$0.056$0.044169,927
$0.053+0.006+13.3%$0.047$0.070$0.047278,004
$0.047-0.005-10.5%$0.047$0.062$0.040202,641
$0.052+0.007+15.6%$0.050$0.060$0.045347,160
$0.045-0.004-9.0%$0.046$0.050$0.041220,560
$0.049+0.000+1.0%$0.049$0.060$0.043422,760
$0.049+0.008+19.2%$0.031$0.052$0.0311,047,987
$0.041+0.003+7.0%$0.041$0.041$0.035623,491
$0.038+0.003+8.8%$0.035$0.050$0.034289,346
$0.035-0.010-21.6%$0.047$0.051$0.032391,678
$0.045+0.000+1.0%$0.052$0.052$0.032838,101
$0.045-0.017-27.6%$0.052$0.069$0.0401,115,914
$0.062+0.004+6.0%$0.051$0.070$0.051291,674
$0.058-0.017-22.8%$0.061$0.075$0.051153,616
$0.075+0.008+12.3%$0.063$0.080$0.050308,741
$0.067+0.022+49.7%$0.049$0.071$0.0411,165,050
$0.0450.000-0.9%$0.040$0.050$0.040597,837
$0.045-0.006-11.6%$0.040$0.055$0.032509,413
$0.051+0.001+2.0%$0.052$0.058$0.045485,472
$0.050+0.003+6.4%$0.044$0.057$0.040953,200
$0.047+0.004+9.5%$0.043$0.060$0.0344,103,000
$0.043-0.031-41.9%$0.019$0.044$0.0196,288,291
$0.074-0.044-37.4%$0.091$0.094$0.06947,480,718
$0.118+0.011+10.3%$0.120$0.127$0.110151,001,600
$0.107-0.030-21.9%$0.130$0.197$0.10646,794,600
$0.137-0.026-16.0%$0.140$0.142$0.12015,689,100
$0.163-0.018-9.9%$0.151$0.170$0.14210,782,700
$0.181-0.538-74.8%$0.224$0.230$0.15758,562,800
$0.719-0.061-7.8%$0.749$0.763$0.7001,084,200
$0.780+0.038+5.1%$0.758$0.785$0.736900,300
$0.742-0.019-2.5%$0.783$0.811$0.7111,580,400
$0.761-0.043-5.3%$0.800$0.833$0.7511,119,800
$0.804+0.005+0.6%$0.810$0.859$0.7921,239,600
$0.799-0.028-3.4%$0.840$0.840$0.798902,300
$0.827+0.035+4.4%$0.790$0.864$0.790797,600
$0.792-0.098-11.0%$0.850$0.896$0.7801,848,100
$0.890-0.300-25.2%$1.030$1.030$0.8502,199,600
$1.190+0.060+5.3%$1.110$1.240$1.0152,031,400
$1.130+0.070+6.6%$1.100$1.160$1.0501,087,200
$1.060+0.128+13.7%$0.960$1.090$0.9601,112,500
$0.932+0.004+0.4%$0.965$1.020$0.922922,500
$0.928+0.026+2.9%$0.900$0.958$0.893639,100
$0.902+0.072+8.7%$0.840$0.920$0.840526,200
$0.830-0.011-1.3%$0.840$0.850$0.800355,400
$0.841-0.020-2.3%$0.870$0.886$0.840319,900
$0.861+0.013+1.5%$0.860$0.890$0.860457,400
$0.848+0.040+5.0%$0.814$0.880$0.800695,500
$0.808+0.015+1.9%$0.794$0.840$0.780499,500
$0.793-0.009-1.1%$0.790$0.813$0.746763,400
Ticker
gettex:BX20
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
gettex
Currency
EUR

What changed lately

Latest news

All BioXcel Therapeutics, Inc. news

BioXcel Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
16 in the last 12 months · 173 in all · newest May 28, 2026 · oldest 2019
Calls
14 calls with a replay · 14 with a transcript · latest Nov 14, 2024
Decks
22 decks · latest November 2025

Where BioXcel Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:BTAI · Home listingNASDAQUnited StatesUSD
BOATS:BTAIBOATSUnited StatesUSD
LS Exchange:A40YSRLS ExchangeGermanyEUR
gettex:BX20 · This pagegettexGermanyEUR
Lang & Schwarz:A40YSRLang & SchwarzGermanyEUR
Tradegate:BX20TradegateGermanyEUR
Dusseldorf:BX20DusseldorfGermanyEUR
Frankfurt:BX20FrankfurtGermanyEUR
Hamburg:BX20HamburgGermanyEUR
Munich:BX20MunichGermanyEUR
Stuttgart:BX20StuttgartGermanyEUR

Valuation

EV/sales 124× against a median of −0.1×: the highest of 3 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Oct 30, 2026

Enterprise value
$92.02M USD
P/E
Loss
EV/sales
124×
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
53.1%
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
Negative equity
Beta vs S&P 500
2.39

Biotechnology: the 10 companies nearest in size, of 891 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
BioXcel Therapeutics, Inc. · NASDAQ:BTAIUS$406,965US$92.02Mn/a124×n/an/an/an/a2.39
Protagenic Therapeutics, Inc. · OTC:PTIXUS$687,879US$610,9700.1×n/an/a0.6×n/a0.0×1.21
Lakewood-Amedex Biotherapeutics Inc. · NASDAQ:LABTUS$580,337−US$2.74Mn/an/an/a0.2×n/a0.0×0.46
Mushrooms, Inc. · OTC:MSRMUS$539,339US$564,177n/an/an/an/an/an/a1.24
Jaguar Health, Inc. · NASDAQ:JAGXUS$527,406−US$1.48Mn/a−0.1×n/a0.0×−181.8%0.2×3.75
Altamira Therapeutics Ltd. · OTC:CYTOFUS$404,655US$400,900n/an/an/a0.1×n/a0.0×0.64
NKGen Biotech Inc. · OTC:NKGNUS$391,807US$38.58Mn/an/an/an/an/an/a0.88
Vaxil Bio Ltd. · TSXV:VXLUS$319,522−US$4,0711.2×n/an/a0.4×n/a0.0×-0.16
Chimeric Therapeutics Limited · ASX:CHMUS$292,816−US$220,193n/a−0.1×n/a0.2×−262.8%2.5×n/a
CERo Therapeutics Holdings, Inc. · OTC:CEROUS$265,035−US$190,890n/an/an/an/an/an/a1.47
CDT Equity Inc. · NASDAQ:CDTUS$234,109−US$1.49Mn/an/an/a0.0×n/a0.0×1.14
Median of the othersUS$398,231−US$97,4810.7×−0.1×0.2×−222.3%0.0×1.14

Team and board

OfficerRole
Vimal MehtaChief Executive Officer & Founder
Richard I. SteinhartSenior Vice President and Chief Financial Officer
Javier RodriguezSenior Vice President, Chief Legal Officer, and Corporate Secretary
Frank D. YoccaChief Scientific Officer

Events

CallWhenStatus
BioXcel Therapeutics (NASDAQ:BTAI) Q3 2024 Earnings CallThu, Nov 14, 2024 · 8:00 AM ETReplay
BioXcel Therapeutics (NASDAQ:BTAI) Q2 2024 Earnings CallTue, Aug 06, 2024 · 8:00 AM ETReplay
BioXcel Therapeutics (NASDAQ:BTAI) Q1 2024 Earnings CallThu, May 09, 2024 · 8:00 AM ETReplay
BioXcel Therapeutics (NASDAQ:BTAI) Q4 2023 Earnings CallTue, Mar 12, 2024 · 8:00 AM ETReplay
BioXcel Therapeutics (NASDAQ:BTAI) Q3 2023 Earnings CallTue, Nov 14, 2023 · 8:00 AM ETReplay
BioXcel Therapeutics (NASDAQ:BTAI) Q2 2023 Earnings CallMon, Aug 14, 2023 · 8:00 AM ETReplay
BioXcel Therapeutics (NASDAQ:BTAI) Q1 2023 Earnings CallMon, May 08, 2023 · 8:00 AM ETReplay
BioXcel Therapeutics (NASDAQ:BTAI) Q4 2022 Earnings CallThu, Mar 09, 2023 · 8:30 AM ETReplay
BioXcel Therapeutics (NASDAQ:BTAI) Q3 2022 Earnings CallThu, Nov 10, 2022 · 8:30 AM ETReplay
BioXcel Therapeutics (NASDAQ:BTAI) Q2 2022 Earnings CallTue, Aug 09, 2022 · 8:30 AM ETReplay
All 14 calls
CallWhenStatus
BioXcel Therapeutics (NASDAQ:BTAI) Q1 2022 Earnings CallMon, May 09, 2022 · 8:30 AM ETReplay
BioXcel Therapeutics (NASDAQ:BTAI) Q4 2021 Earnings CallThu, Mar 10, 2022 · 8:30 AM ETReplay
BioXcel Therapeutics (NASDAQ:BTAI) Q3 2021 Earnings CallWed, Nov 10, 2021 · 8:30 AM ETReplay
BioXcel Therapeutics (NASDAQ:BTAI) Q2 2021 Earnings CallTue, Aug 10, 2021 · 8:30 AM ETReplay

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2025)Investor deck45 slidesNovember 2025
Technical Presentation (August 2025)Technical24 slidesAug 27, 2025
Investor Presentation (August 2025)Investor deck15 slidesAug 11, 2025
Investor Presentation (April 2024)Investor deck36 slidesApr 22, 2024
Corporate Update (April 2024)Corporate update8 slidesApr 10, 2024
Investor Presentation (February 2024)Investor deck42 slidesFeb 14, 2024
Investor Day (December 2023)Investor day59 slidesDec 12, 2023
Investor Presentation (October 2023)Investor deck27 slidesOct 10, 2023
Technical Presentation (February 2023)Technical86 slidesFeb 21, 2023
Technical Presentation (February 2023)Technical5 slidesFeb 21, 2023
All 22 decks
DeckKindSlidesDate
41st Annual J.P. Morgan Healthcare Conference 2023Conference28 slidesJan 11, 2023
Investor Day (October 2022)Investor day96 slidesOct 18, 2022
Investor Presentation (September 2022)Investor deck7 slidesSep 12, 2022
Corporate Update (2022)Corporate update10 slides2022
Investor Presentation (April 2020)Investor deck30 slidesApr 15, 2020
Investor Presentation (December 2019)Investor deck26 slidesDecember 2019
Corporate Update (July 2019)Corporate update21 slidesJul 22, 2019
Investor Presentation (May 2019)Investor deck17 slidesMay 20, 2019
Investor Presentation (March 2019)Investor deck35 slidesMar 12, 2019
Corporate Update (January 2019)Corporate update16 slidesJan 3, 2019
Investor Presentation (June 2018)Investor deck26 slidesJun 7, 2018
Investor Presentation (May 2018)Investor deck27 slidesMay 21, 2018

Open Decks

Financings

RaiseDate
At-the-market programme of common stock
Closed: US$11.5M raised
Aug 12, 2025
Warrant exercise of outstanding warrants
Closed: US$3.6M raised
Aug 12, 2025
Registered direct offering of shares of common stock (or common stock equivalents) and accompanying warrants
Closed: US$14M raised · US$3.5 a share · Warrants at US$4.2 for 60 months · Rodman & Renshaw LLC
Dealers: Rodman & Renshaw LLC (lead)
Use of proceeds: Working capital and general corporate purposes
Mar 4, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$11.00 a share on Mar 7, 2018.

Price
US$11.00 a share
Shares offered
5,454,545 shares of common stock
Offering size
US$60 million
Underwriters' option
Up to 818,181 more shares
Listing
BTAI on the Nasdaq Capital Market
Underwriters
Barclays, UBS Investment Bank, BMO Capital Markets, Canaccord Genuity · In the order on the cover
Shares delivered
On or about Mar 12, 2018

Steps

StepWhen
Draft sent to the SEC in confidenceNov 13, 2017
Filed publiclyFeb 12, 2018
Amended 3 timesNewest Mar 5, 2018
Shares registered with an exchangeMar 5, 2018
Declared effective by the SECMar 7, 2018
Final prospectus, with the priceMar 9, 2018

Open IPO · From the cover of the final prospectus (424B4) filed Mar 9, 2018

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue642.0K2.27M1.38M375.0K
Cost of revenue164.0K2.14M1.26M20.0K
Gross profit478.0K123.0K120.0K355.0K
Research and development30.3M30.4M84.3M91.2M52.7M58.0M25.8M14.6M2.69M
Selling, general and administrative20.5M34.5M83.4M68.8M54.2M
Operating income-50.5M-67.2M-171.8M-159.6M-106.9M-82.3M-33.6M-20.0M-4.54M
Depreciation and amortization300.0K309.0K318.0K327.0K297.0K188.0K156.0K17.0K1.00K
EBITDA-50.2M-66.9M-171.5M-159.3M-106.6M-82.1M-33.4M-19.9M-4.54M
Interest expense17.0M15.1M13.3M8.21M40.0K27.0K20.0K
Income tax000
Net income-69.9M-59.6M-179.1M-165.8M-106.9M-82.2M-33.0M-19.3M-4.54M
Earnings per share, basic-5.73-23.51-98.33-5.92-4.05-3.79-2.02-1.32-0.47
Earnings per share, diluted-5.73-23.51-98.33-5.92-4.05-3.79-2.02-1.32-0.47

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents28.4M29.9M65.2M193.7M233.0M213.1M32.4M42.6M887.0K
Receivables233.0K131.0K71.0K248.0K
Inventory722.0K679.0K1.99M1.99M
Current assets44.7M37.4M72.1M202.9M236.8M217.1M34.1M43.2M890.0K
Property, plant and equipment175.0K475.0K784.0K1.08M1.29M1.27M1.04M327.0K4.00K
Total assets44.9M38.3M73.7M205.9M239.4M219.9M36.4M43.5M1.35M
Accounts payable14.7M16.0M13.7M10.2M4.68M3.98M4.95M1.60M444.0K
Current liabilities53.9M22.2M27.3M32.9M16.7M11.8M8.47M4.66M2.34M
Long-term debt84.7M102.5M100.6M93.1M
Total debt109.6M102.5M100.6M93.1M
Total liabilities140.4M131.4M130.2M129.1M17.8M13.2M9.50M4.66M2.34M
Shareholders' equity-95.5M-93.1M-56.5M76.8M221.7M206.7M26.9M38.9M-982.0K
Shares outstanding22.3M3.10M1.87M28.1M28.0M24.4M18.1M15.7M9.91M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-57.6M-72.0M-155.0M-135.3M-82.2M-66.3M-27.1M-13.5M-2.20M
Capital spending00-20.0K-139.0K-445.0K-316.0K-870.0K-340.0K
Free cash flow-57.6M-72.0M-155.0M-135.5M-82.6M-66.7M-28.0M-13.8M
Cash from investing00-20.0K-139.0K-445.0K-316.0K-870.0K-340.0K
Cash from financing56.5M36.7M26.5M96.2M102.4M247.4M17.8M55.5M3.08M
Share buybacks-9.02M
Change in cash-1.10M-35.4M-128.5M-39.2M19.8M180.7M-10.1M41.7M887.0K

Open Financials

Filings

FilingDateTypeFiled with
NT 10-Q · Late filing noticeNov 17, 2026Explanation requestSEC
8-K · Current reportOct 30, 2026Acquisition or disposalSEC
8-K · Current reportSep 1, 2026FinancingSEC
8-K · Current reportAug 28, 2026Material contractSEC
8-K · Current reportAug 25, 2026Material contractSEC
8-K · Current reportAug 24, 2026Material contractSEC
4 · Change in ownershipAug 14, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 14, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 13, 2026Quarterly reportSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportAug 11, 2026Material contractSEC
8-K · Current reportAug 3, 2026Material contractSEC
8-K · Current reportJul 6, 2026Material contractSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
144 · Notice of proposed saleMay 20, 2026Other filingsSEC
144 · Notice of proposed saleMay 20, 2026Other filingsSEC
144 · Notice of proposed saleMay 20, 2026Other filingsSEC
144 · Notice of proposed saleMay 20, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
8-K · Current reportMay 15, 2026ResultsSEC
10-Q · Quarterly reportMay 15, 2026Quarterly reportSEC
4 · Change in ownershipMay 7, 2026Insider tradeSEC
4 · Change in ownershipMay 7, 2026Insider tradeSEC
4 · Change in ownershipMay 7, 2026Insider tradeSEC
4 · Change in ownershipMay 7, 2026Insider tradeSEC
8-K · Current reportApr 17, 2026FinancingSEC
8-K · Current reportApr 1, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 30, 2026Big-stake noticeSEC
S-8 · Registration statement for employee plansMar 27, 2026Offer documentSEC
10-K · Annual reportMar 27, 2026Annual reportSEC
8-K · Current reportMar 27, 2026ResultsSEC
4 · Change in ownershipMar 16, 2026Insider tradeSEC
4 · Change in ownershipMar 16, 2026Insider tradeSEC
4 · Change in ownershipMar 16, 2026Insider tradeSEC
4 · Change in ownershipMar 16, 2026Insider tradeSEC
8-K · Current reportMar 11, 2026Material contractSEC
424B5 · ProspectusMar 11, 2026Offer documentSEC
8-K · Current reportFeb 12, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 9, 2026Big-stake noticeSEC
8-K · Current reportFeb 6, 2026Management or board changeSEC
8-K · Current reportJan 20, 2026Current reportSEC
4 · Change in ownershipJan 12, 2026Insider tradeSEC
4 · Change in ownershipJan 12, 2026Insider tradeSEC
4 · Change in ownershipJan 12, 2026Insider tradeSEC
4 · Change in ownershipJan 12, 2026Insider tradeSEC
4 · Change in ownershipJan 12, 2026Insider tradeSEC
4 · Change in ownershipJan 12, 2026Insider tradeSEC
4 · Change in ownershipJan 12, 2026Insider tradeSEC
8-K · Current reportJan 12, 2026Current reportSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipDec 15, 2025Insider tradeSEC
4 · Change in ownershipDec 15, 2025Insider tradeSEC
4 · Change in ownershipDec 15, 2025Insider tradeSEC
4 · Change in ownershipDec 15, 2025Insider tradeSEC
8-K · Current reportDec 15, 2025Meeting outcomeSEC
ARS · Annual report to shareholdersNov 12, 2025Annual reportSEC
DEF 14A · Proxy statementNov 12, 2025Meeting noticeSEC
10-Q · Quarterly reportNov 12, 2025Quarterly reportSEC
8-K · Current reportNov 12, 2025ResultsSEC
8-K · Current reportNov 10, 2025Current reportSEC
4 · Change in ownershipNov 3, 2025Insider tradeSEC
PRE 14A · Preliminary proxy statementOct 31, 2025Meeting noticeSEC
8-K · Current reportOct 30, 2025Current reportSEC
8-K · Current reportOct 14, 2025Current reportSEC
4 · Change in ownershipOct 1, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeOct 1, 2025Big-stake noticeSEC
4 · Change in ownershipSep 16, 2025Insider tradeSEC
4 · Change in ownershipSep 16, 2025Insider tradeSEC
4 · Change in ownershipSep 16, 2025Insider tradeSEC
4 · Change in ownershipSep 16, 2025Insider tradeSEC
8-K · Current reportSep 15, 2025Current reportSEC
8-K · Current reportSep 10, 2025Current reportSEC
4 · Change in ownershipSep 2, 2025Insider tradeSEC
8-K · Current reportAug 27, 2025Current reportSEC
424B5 · ProspectusAug 18, 2025Offer documentSEC
8-K · Current reportAug 18, 2025Current reportSEC
8-K · Current reportAug 18, 2025Current reportSEC
8-K · Current reportAug 15, 2025Current reportSEC
10-Q · Quarterly reportAug 12, 2025Quarterly reportSEC
8-K · Current reportAug 12, 2025ResultsSEC
8-K · Current reportAug 11, 2025Current reportSEC
8-K · Current reportAug 11, 2025Current reportSEC
8-K · Current reportAug 6, 2025Current reportSEC
424B5 · ProspectusAug 6, 2025Offer documentSEC
4 · Change in ownershipAug 5, 2025Insider tradeSEC
4 · Change in ownershipAug 5, 2025Insider tradeSEC
4 · Change in ownershipAug 5, 2025Insider tradeSEC
4 · Change in ownershipAug 5, 2025Insider tradeSEC
8-K · Current reportAug 1, 2025Current reportSEC
4 · Change in ownershipJul 31, 2025Insider tradeSEC
4 · Change in ownershipJul 22, 2025Insider tradeSEC
4 · Change in ownershipJul 22, 2025Insider tradeSEC
4 · Change in ownershipJul 22, 2025Insider tradeSEC
4 · Change in ownershipJul 22, 2025Insider tradeSEC
8-K · Current reportJul 21, 2025Current reportSEC
8-K · Current reportJul 15, 2025Current reportSEC
4 · Change in ownershipJun 30, 2025Insider tradeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
8-K · Current reportMay 27, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 12, 2025Quarterly reportSEC
8-K · Current reportMay 12, 2025ResultsSEC
4 · Change in ownershipMay 1, 2025Insider tradeSEC
S-8 · Registration statement for employee plansApr 4, 2025Offer documentSEC
8-K · Current reportApr 3, 2025Material contractSEC
424B5 · ProspectusApr 3, 2025Offer documentSEC
4 · Change in ownershipApr 1, 2025Insider tradeSEC
4 · Change in ownershipApr 1, 2025Insider tradeSEC
4 · Change in ownershipApr 1, 2025Insider tradeSEC
4 · Change in ownershipApr 1, 2025Insider tradeSEC
4 · Change in ownershipApr 1, 2025Insider tradeSEC
4 · Change in ownershipApr 1, 2025Insider tradeSEC
4 · Change in ownershipApr 1, 2025Insider tradeSEC
10-K · Annual reportMar 28, 2025Annual reportSEC
8-K · Current reportMar 27, 2025ResultsSEC
8-K · Current reportMar 21, 2025Current reportSEC
8-K · Current reportMar 21, 2025Current reportSEC
4 · Change in ownershipMar 17, 2025Insider tradeSEC
4 · Change in ownershipMar 17, 2025Insider tradeSEC
4 · Change in ownershipMar 17, 2025Insider tradeSEC
4 · Change in ownershipMar 17, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
8-K · Current reportMar 4, 2025Material contractSEC
424B5 · ProspectusMar 4, 2025Offer documentSEC
8-K · Current reportMar 3, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeFeb 14, 2025Big-stake noticeSEC
8-K · Current reportFeb 6, 2025Current reportSEC
4 · Change in ownershipFeb 4, 2025Insider tradeSEC
8-K · Current reportJan 29, 2025Meeting outcomeSEC
EFFECT · Notice that a registration is effectiveJan 21, 2025Other filingsSEC
4 · Change in ownershipJan 16, 2025Insider tradeSEC
3 · Initial statement of ownershipJan 16, 2025Insider tradeSEC
8-K · Current reportJan 16, 2025Management or board changeSEC
CORRESP · Letter to the SECJan 15, 2025Other filingsSEC
UPLOAD · Letter from the SECJan 15, 2025Other filingsSEC
4 · Change in ownershipJan 10, 2025Insider tradeSEC
4 · Change in ownershipJan 10, 2025Insider tradeSEC
4 · Change in ownershipJan 10, 2025Insider tradeSEC
S-3 · Registration statementJan 10, 2025Offer documentSEC
8-K · Current reportJan 8, 2025Management or board changeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
DEF 14A · Proxy statementDec 30, 2024Meeting noticeSEC
SCHEDULE 13G · Big-stake noticeDec 18, 2024Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeDec 18, 2024Big-stake noticeSEC
PRE 14A · Preliminary proxy statementDec 18, 2024Meeting noticeSEC
4 · Change in ownershipDec 17, 2024Insider tradeSEC
4 · Change in ownershipDec 17, 2024Insider tradeSEC
4 · Change in ownershipDec 17, 2024Insider tradeSEC
4 · Change in ownershipDec 17, 2024Insider tradeSEC
4 · Change in ownershipDec 17, 2024Insider tradeSEC
144 · Notice of proposed saleDec 16, 2024Other filingsSEC
144 · Notice of proposed saleDec 16, 2024Other filingsSEC
144/A · Notice of proposed sale, amendedDec 16, 2024Other filingsSEC
144 · Notice of proposed saleDec 16, 2024Other filingsSEC
144 · Notice of proposed saleDec 16, 2024Other filingsSEC
144 · Notice of proposed saleDec 16, 2024Other filingsSEC
4/A · Change in ownership, amendedDec 4, 2024Insider tradeSEC
4 · Change in ownershipDec 3, 2024Insider tradeSEC
8-K · Current reportNov 25, 2024Material contractSEC
4 · Change in ownershipNov 25, 2024Insider tradeSEC
3 · Initial statement of ownershipNov 25, 2024Insider tradeSEC
424B5 · ProspectusNov 25, 2024Offer documentSEC
424B5 · ProspectusNov 21, 2024Offer documentSEC
8-K · Current reportNov 21, 2024Material contractSEC
10-Q · Quarterly reportNov 14, 2024Quarterly reportSEC
8-K · Current reportNov 14, 2024ResultsSEC
8-K · Current reportOct 9, 2024Management or board changeSEC
4 · Change in ownershipOct 3, 2024Insider tradeSEC
4 · Change in ownershipOct 3, 2024Insider tradeSEC
4 · Change in ownershipOct 3, 2024Insider tradeSEC
4 · Change in ownershipOct 3, 2024Insider tradeSEC
4 · Change in ownershipOct 3, 2024Insider tradeSEC
144 · Notice of proposed saleOct 3, 2024Other filingsSEC
144 · Notice of proposed saleOct 3, 2024Other filingsSEC
144 · Notice of proposed saleOct 3, 2024Other filingsSEC
144 · Notice of proposed saleOct 3, 2024Other filingsSEC
144 · Notice of proposed saleOct 3, 2024Other filingsSEC
8-K · Current reportSep 20, 2024Current reportSEC
8-K · Current reportSep 19, 2024Management or board changeSEC
4 · Change in ownershipSep 17, 2024Insider tradeSEC
4 · Change in ownershipSep 17, 2024Insider tradeSEC
4 · Change in ownershipSep 17, 2024Insider tradeSEC
4 · Change in ownershipSep 17, 2024Insider tradeSEC
4 · Change in ownershipSep 17, 2024Insider tradeSEC
4 · Change in ownershipSep 17, 2024Insider tradeSEC

This page holds 200 of 673 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from BioXcel Therapeutics, Inc.’s releases · as of Aug 12, 2025

Common shares
31,305,000
Fully diluted
31,305,000

Fully diluted

LineShares
Common shares31,305,000

Warrants and options

Lot
Warrants · US$4.20 · expire about Mar 2030

Share count over time

CountShares
Nov 22, 202631,305,000

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
BROOKFIELD Corp1.63M5.2%US$80,437Sep 30, 2026
Flow Traders U.S. LLC22,9460.07%US$1,000Sep 30, 2026
Farther Finance Advisors, LLC25<0.01%US$1Sep 30, 2026
IFP Advisors, Inc13<0.01%US$1Sep 30, 2026
Barclays1<0.01%Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund680K2.2%US$958KJun 30, 2026
Vanguard Extended Market Index Fund207K0.66%US$292KJun 30, 2026
Fidelity Extended Market Index Fund106K0.34%US$124KMay 31, 2026
Select Biotechnology Portfolio90,3000.29%US$106KMay 31, 2026
iShares Micro-Cap ETF89,2050.28%US$126KJun 30, 2026
Fidelity Total Market Index Fund34,2370.11%US$40,057May 31, 2026
Fidelity Series Total Market Index Fund29,5460.09%US$34,569May 31, 2026
Fidelity Nasdaq Composite Index Fund10,8720.03%US$12,720May 31, 2026
1290 VT Micro Cap Portfolio5,9460.02%US$8,384Jun 30, 2026
Total Stock Market Index Trust651<0.01%US$918Jun 30, 2026

Insider trades

TradeTradeSharesPriceValueDate
Mehta Vimal
Director, Officer: CEO and President
Sale19,419USD 1.09US$21,167May 20, 2026
Steinhart Richard I
Officer: Chief Financial Officer
Sale6,845USD 1.09US$7,461May 20, 2026
Rodriguez Javier
Officer: See Remarks
Sale6,560USD 1.08US$7,085May 20, 2026
Yocca Frank
Officer: Chief Scientific Officer
Sale6,845USD 1.09US$7,461May 20, 2026

Big stakes

StakeStakeSharesDateFiling
Integrated Core Strategies (US) LLC8.40%1.83MDec 31, 2025Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Rajiv Patni
Other companies: Septerna, Inc. (Chief Medical Officer · Since at least Aug 24, 2026); Quince Therapeutics, Inc. (Director · Since at least Feb 15, 2024); Reata Pharmaceuticals Inc (EVP, Chief R&D Officer · Jun 12, 2023 – Sep 26, 2023 · Past); Portola Pharmaceuticals Inc (EVP, CMO · Feb 3, 2020 – Jul 2, 2020 · Past); Adamas Pharmaceuticals Inc (Chief Medical Officer · Jun 8, 2015 – Apr 8, 2019 · Past); Ocera Therapeutics Inc (Chief Development Officer · Sep 2, 2014 – May 7, 2015 · Past)
Director · Since at least Jan 15, 2025
Michael P. Miller
Other companies: Rigel Pharmaceuticals, Inc. (Director · Since at least Feb 1, 2026); Puma Biotechnology Inc (Director · Since at least Feb 23, 2018); Jazz Pharmaceuticals plc (EVP, US Commercial · Jul 31, 2014 – Mar 12, 2020 · Past); VIVUS Inc (Chief Commercial Officer · Apr 26, 2010 – Jan 25, 2013 · Past)
Director · Since at least Jul 1, 2022
Richard I. Steinhart
Other companies: Atossa Therapeutics, Inc. (Director · Since at least Mar 1, 2014); Actinium Pharmaceuticals, Inc. (Delaware) (Director · Since at least Nov 8, 2013); MELA Sciences Inc (Chief Financial Officer · May 14, 2010 – Aug 5, 2013 · Past); TG Therapeutics, Inc. (Director · Mar 25, 2008 – Mar 3, 2010 · Past)
Senior Vice President and Chief Financial Officer · Since at least Mar 7, 2018
Matthew T Wiley
Other companies: Definium Therapeutics, Inc. (Chief Commercial Officer · Since at least Mar 17, 2025); VYNE Therapeutics Inc. (Chief Commercial Officer · Sep 30, 2020 – Jun 30, 2021 · Past)
Chief Commercial Officer · Jan 17, 2022 – Sep 17, 2024 · Past
Sandeep Steve Laumas
Other companies: Unicycive Therapeutics, Inc. (Director · Since at least Jul 12, 2021); Instil Bio, Inc. (Chief Financial Officer & Chief Business Officer · Since at least Mar 18, 2021)
Director · Since at least Mar 7, 2018
William P Kane Jr
Other companies: LB Pharmaceuticals Inc (Director · Since at least Sep 10, 2025); Karuna Therapeutics Inc (Chief Commercial Officer · Feb 6, 2023 – Mar 18, 2024 · Past)
Chief Commercial Officer · Jun 15, 2020 – Aug 16, 2021 · Past
David J Mack
Other companies: Ambipar Emergency Response (Director · Since at least Mar 18, 2026)
Director · Since at least Nov 21, 2024
June Bray
Other companies: Quince Therapeutics, Inc. (Director · Since at least Jun 9, 2022)
Director · Since at least Mar 1, 2021
Michal Votruba
Other companies: Emmaus Life Sciences, Inc. (Director · Jul 30, 2015 – Oct 8, 2018 · Past)
Director · Since at least Mar 7, 2019
Susan E Atkins
Other companies: Jefferson Capital, Inc. (Director · Since at least Mar 18, 2026)
Director · Since at least Aug 12, 2026
All 17 people
PersonSeat
Vincent O'Neill
Other companies: Synlogic Inc (Chief Medical Officer · Apr 25, 2016 – Apr 25, 2016 · Past)
See Remarks · Mar 7, 2018 – Dec 14, 2024 · Past
Frank D. YoccaChief Scientific Officer · Since at least Mar 7, 2018
Javier RodriguezSenior Vice President, Chief Legal Officer, and Corporate Secretary · Since at least Feb 22, 2021
Krishnan NandabalanDirector · Jul 24, 2020 – Apr 6, 2023 · Past
Peter MuellerDirector · Since at least Jun 11, 2021
Reina BenabouSee Remarks · Jun 22, 2020 – Jun 22, 2020 · Past
Vimal MehtaCEO and President, Director · Since at least May 23, 2019

Open People

Log in to ask 6ix AI your own questions about BioXcel Therapeutics, Inc.